|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRRD |
Gene summary for SRRD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRRD | Gene ID | 402055 |
| Gene name | SRR1 domain containing | |
| Gene Alias | HC/HCC | |
| Cytomap | 22q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | Q9UH36 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 402055 | SRRD | LZE24T | Human | Esophagus | ESCC | 5.17e-08 | 1.69e-01 | 0.0596 |
| 402055 | SRRD | P2T-E | Human | Esophagus | ESCC | 2.93e-15 | 2.17e-01 | 0.1177 |
| 402055 | SRRD | P4T-E | Human | Esophagus | ESCC | 7.22e-06 | 1.54e-01 | 0.1323 |
| 402055 | SRRD | P5T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.05e-01 | 0.1327 |
| 402055 | SRRD | P9T-E | Human | Esophagus | ESCC | 5.64e-03 | 7.81e-02 | 0.1131 |
| 402055 | SRRD | P10T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.28e-01 | 0.116 |
| 402055 | SRRD | P12T-E | Human | Esophagus | ESCC | 3.50e-02 | 8.13e-02 | 0.1122 |
| 402055 | SRRD | P15T-E | Human | Esophagus | ESCC | 5.71e-05 | 1.31e-01 | 0.1149 |
| 402055 | SRRD | P16T-E | Human | Esophagus | ESCC | 5.10e-03 | 1.15e-01 | 0.1153 |
| 402055 | SRRD | P20T-E | Human | Esophagus | ESCC | 1.76e-03 | 7.93e-02 | 0.1124 |
| 402055 | SRRD | P22T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.77e-01 | 0.1236 |
| 402055 | SRRD | P23T-E | Human | Esophagus | ESCC | 3.80e-06 | 1.47e-01 | 0.108 |
| 402055 | SRRD | P24T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.54e-01 | 0.1287 |
| 402055 | SRRD | P26T-E | Human | Esophagus | ESCC | 5.38e-06 | 1.74e-01 | 0.1276 |
| 402055 | SRRD | P28T-E | Human | Esophagus | ESCC | 4.44e-08 | 1.54e-01 | 0.1149 |
| 402055 | SRRD | P30T-E | Human | Esophagus | ESCC | 4.66e-03 | 1.80e-01 | 0.137 |
| 402055 | SRRD | P31T-E | Human | Esophagus | ESCC | 3.01e-03 | 1.44e-01 | 0.1251 |
| 402055 | SRRD | P32T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.27e-01 | 0.1666 |
| 402055 | SRRD | P37T-E | Human | Esophagus | ESCC | 5.34e-05 | 1.60e-01 | 0.1371 |
| 402055 | SRRD | P38T-E | Human | Esophagus | ESCC | 1.23e-07 | 3.50e-01 | 0.127 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
| GO:000762319 | Esophagus | ESCC | circadian rhythm | 119/8552 | 210/18723 | 8.47e-04 | 4.36e-03 | 119 |
| GO:00067791 | Esophagus | ESCC | porphyrin-containing compound biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
| GO:00330141 | Esophagus | ESCC | tetrapyrrole biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
| GO:00461482 | Esophagus | ESCC | pigment biosynthetic process | 40/8552 | 62/18723 | 2.14e-03 | 9.54e-03 | 40 |
| GO:00067832 | Esophagus | ESCC | heme biosynthetic process | 20/8552 | 27/18723 | 2.61e-03 | 1.11e-02 | 20 |
| GO:00330132 | Esophagus | ESCC | tetrapyrrole metabolic process | 37/8552 | 59/18723 | 6.23e-03 | 2.29e-02 | 37 |
| GO:00424401 | Esophagus | ESCC | pigment metabolic process | 50/8552 | 84/18723 | 7.34e-03 | 2.64e-02 | 50 |
| GO:00421681 | Esophagus | ESCC | heme metabolic process | 27/8552 | 42/18723 | 1.16e-02 | 3.90e-02 | 27 |
| GO:00427529 | Esophagus | ESCC | regulation of circadian rhythm | 68/8552 | 121/18723 | 1.27e-02 | 4.21e-02 | 68 |
| GO:004851116 | Oral cavity | OSCC | rhythmic process | 157/7305 | 298/18723 | 1.00e-06 | 1.36e-05 | 157 |
| GO:000762316 | Oral cavity | OSCC | circadian rhythm | 110/7305 | 210/18723 | 5.40e-05 | 4.48e-04 | 110 |
| GO:00461481 | Oral cavity | OSCC | pigment biosynthetic process | 36/7305 | 62/18723 | 1.82e-03 | 8.57e-03 | 36 |
| GO:00067831 | Oral cavity | OSCC | heme biosynthetic process | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
| GO:000762323 | Skin | cSCC | circadian rhythm | 89/4864 | 210/18723 | 1.55e-07 | 3.51e-06 | 89 |
| GO:004851123 | Skin | cSCC | rhythmic process | 110/4864 | 298/18723 | 1.83e-05 | 2.19e-04 | 110 |
| GO:004275221 | Skin | cSCC | regulation of circadian rhythm | 48/4864 | 121/18723 | 6.58e-04 | 4.73e-03 | 48 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRRD | SNV | Missense_Mutation | c.364N>A | p.Val122Met | p.V122M | Q9UH36 | protein_coding | tolerated(0.08) | benign(0.023) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SRRD | deletion | Frame_Shift_Del | novel | c.874delG | p.Asp292IlefsTer12 | p.D292Ifs*12 | Q9UH36 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SRRD | SNV | Missense_Mutation | c.997G>A | p.Glu333Lys | p.E333K | Q9UH36 | protein_coding | tolerated(0.74) | benign(0) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SRRD | SNV | Missense_Mutation | rs373728190 | c.220N>C | p.Phe74Leu | p.F74L | Q9UH36 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SRRD | SNV | Missense_Mutation | c.406A>G | p.Thr136Ala | p.T136A | Q9UH36 | protein_coding | tolerated(0.44) | benign(0) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SRRD | SNV | Missense_Mutation | novel | c.792T>A | p.Asn264Lys | p.N264K | Q9UH36 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRRD | SNV | Missense_Mutation | rs377743213 | c.607N>A | p.Glu203Lys | p.E203K | Q9UH36 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SRRD | insertion | In_Frame_Ins | novel | c.567_568insTCCAAAAAT | p.Glu189_Val190insSerLysAsn | p.E189_V190insSKN | Q9UH36 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SRRD | SNV | Missense_Mutation | novel | c.310N>A | p.Leu104Ile | p.L104I | Q9UH36 | protein_coding | tolerated(0.16) | benign(0.382) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| SRRD | SNV | Missense_Mutation | novel | c.299C>A | p.Pro100His | p.P100H | Q9UH36 | protein_coding | deleterious(0.01) | possibly_damaging(0.635) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |